{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:41:22Z","timestamp":1760298082602},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,5,19]],"date-time":"2009-05-19T00:00:00Z","timestamp":1242691200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s12185-009-0327-0","type":"journal-article","created":{"date-parts":[[2009,5,18]],"date-time":"2009-05-18T01:04:07Z","timestamp":1242608647000},"page":"679-688","source":"Crossref","is-referenced-by-count":32,"title":["A Phase I\/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed\/refractory Ph+ ALL"],"prefix":"10.1007","volume":"89","author":[{"given":"Arinobu","family":"Tojo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itsuro","family":"Jinnai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Ohyashiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Miyamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Branford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Tanii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Amagasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Natori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,19]]},"reference":[{"key":"327_CR1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164\u201372. doi: 10.1056\/NEJM199907153410306 .","journal-title":"N Engl J Med"},{"key":"327_CR2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330\u201340. doi: 10.1056\/NEJM199904293401706 .","journal-title":"N Engl J Med"},{"key":"327_CR3","first-page":"49","volume":"25","author":"JE Sokal","year":"1998","unstructured":"Sokal JE, Baccarani M, Russo D, et al. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol. 1998;25:49\u201361.","journal-title":"Semin Hematol"},{"issue":"9","key":"327_CR4","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2005-02-0708","volume":"105","author":"RT Maziarz","year":"2005","unstructured":"Maziarz RT. Ph+ ALL: another success for imatinib. Blood. 2005;105(9):3388\u20139. doi: 10.1182\/blood-2005-02-0708 .","journal-title":"Blood"},{"key":"327_CR5","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004. doi: 10.1056\/NEJMoa022457 .","journal-title":"N Engl J Med"},{"key":"327_CR6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"B Druker","year":"2006","unstructured":"Druker B, Guilhot F, O\u2019Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317. doi: 10.1056\/NEJMoa062867 .","journal-title":"N Engl J Med"},{"key":"327_CR7","doi-asserted-by":"crossref","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. Advance online publication 12 Mar 2009. doi: 10.1038\/leu.2009.38 .","DOI":"10.1038\/leu.2009.38"},{"key":"327_CR8","first-page":"772","volume":"48","author":"PW Manley","year":"2007","unstructured":"Manley PW, Br\u00fcggen J, Fabbro D, et al. Extended kinase profiling of the Bcr-Abl inhibitor nilotinib. Proc Am Assoc Cancer Res. 2007;48:772. Abstract 3249.","journal-title":"Proc Am Assoc Cancer Res"},{"key":"327_CR9","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","volume":"94","author":"E Weisberg","year":"2006","unstructured":"Weisberg E, Manley P, Mestan J, et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94:1765\u20139. doi: 10.1038\/sj.bjc.6603170 .","journal-title":"Br J Cancer"},{"issue":"10","key":"327_CR10","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540\u20136. doi: 10.1182\/blood-2007-03-080689 .","journal-title":"Blood"},{"key":"327_CR11","doi-asserted-by":"crossref","first-page":"226a","DOI":"10.1182\/blood.V110.11.226.226","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Hochhaus A, Cortes J, et al. Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance. Blood. 2007;110:226a. (Abstract 735).","journal-title":"Blood"},{"issue":"4","key":"327_CR12","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","volume":"111","author":"P le Coutre","year":"2008","unstructured":"le Coutre P, Giles FJ, Apperley J, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib resistance or intolerance accelerated-phase chronic myelogenous leukemia. Blood. 2008;111(4):1834\u20139. doi: 10.1182\/blood-2007-04-083196 .","journal-title":"Blood"},{"key":"327_CR13","doi-asserted-by":"crossref","first-page":"310a","DOI":"10.1182\/blood.V110.11.310.310","volume":"110","author":"FJ Giles","year":"2007","unstructured":"Giles FJ, Larson RA, Kantarjian HM, et al. Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib. Blood. 2007;110:310a. (Abstract 1025).","journal-title":"Blood"},{"key":"327_CR14","doi-asserted-by":"crossref","unstructured":"Ottmann OG, Larson RA, Kantarjian HM, et al. Nilotinib in patients (pts) with relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib. Blood. 2007;110:(Abstract 2815).","DOI":"10.1182\/blood.V110.11.2815.2815"},{"key":"327_CR15","doi-asserted-by":"crossref","unstructured":"Tojo A, Miyazaki Y, Usui N, et al. Phase I study of nilotinib in patients from Japan with imatinib-resistant Ph+ chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL). J Clin Oncol. 2007;25:(Abstract 17511).","DOI":"10.1200\/jco.2007.25.18_suppl.17511"},{"key":"327_CR16","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, Giles F, Wunderle L, et al. Nilotinib imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542\u201351. doi: 10.1056\/NEJMoa055104 .","journal-title":"N Engl J Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-009-0327-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-009-0327-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-009-0327-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T08:06:08Z","timestamp":1589789168000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-009-0327-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,19]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["327"],"URL":"https:\/\/doi.org\/10.1007\/s12185-009-0327-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,19]]}}}